LONDON – Glaxosmithkline plc (GSK) has become the latest pharma to buy into artificial intelligence (AI) as a means to increase productivity in discovery, signing a £33 million (US$42.6 million) contract under which Exscientia Ltd. will apply its technology to design 10 preclinical candidates against targets nominated by GSK.